“who understood the probability that the high triglyceride patent loss would result in generic skinny label infringement on Amarin's Vascepa CVD patent label”
Isn’t that what a company in the pharmaceutical industry should know? Amarin played Russian Roulette with their decisions starting with their selection of the Nevada district and many after.